Page 155 - Drug Class Review
P. 155
Drug Effectiveness Review Project
Drugs Authors: Raskind et al. 50 Janssen Research Foundation To evaluate the efficacy and safety of two doses of galantamine compared with placebo over 6 months in patients with mild to moderate AD Setting: Multi-center (33 sites) placebo galantamine N/A 24 or 32 mg/d 6 months 6 months 213 212/211 (423 total) History of cognitive decline that had been gradual in onset and progressive over a period of at least 6 months; diagnosis of probable AD according to the criteria of the NINCDS-ARDA; presence of mild to moderate dementia; MMSE score of 11 to 24 and a score of ≥ 12 o
Alzheimer Year: 2000 Country: US Study design: RCT Sample size: 636 preceding 3 months
Final Report Update 1 Efficacy/Effectiveness STUDY: FUNDING: RESEARCH OBJECTIVE: DESIGN: INTERVENTION: Dose: Duration: Sample size: INCLUSION: EXCLUSION: OTHER MEDICATIONS/ INTERVENTIONS ALLOWED: Alzheimer's Drugs
